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Abstract
Purpose STOPP and START criteria identify potential inap-
propriate prescribing and potential prescribing omissions. It is
unknown whether STOPP/START criteria identify all drug-
related problems. This study aims to determine to what extent
STOPP/START correspond to drug-related problems (DRPs)
identified during a full clinical medication review.
Methods In 13 Dutch community pharmacies, 457
community-dwelling patients aged ≥65 years and using ≥5
drugs, received a full clinical medication review. Community
pharmacists identified potential DRPs and recommendations
by implicit criteria. After completion, all identified DRPs and
recommendations were compared with STOPP and START
criteria by investigators.
Results The total number of potential DRPs identified by
community pharmacists was 1656 in 457 patients (mean 3.6
per patient). Eighty-one percent of DRPs were not associated
with STOPP/START criteria. The percentage of START
criteria present in identified DRPs was higher than the per-
centage of STOPP criteria (13 vs. 5.7 %, p<0.01).
The implementation rate for recommendations associated
with STOPP criteria was higher compared to recommenda-
tions associated with START criteria (56 vs. 39 %, p<0.01).
Both implementation rates of STOPP and START recommen-
dations were lower compared to recommendations not asso-
ciated with STOPP/START criteria (66 %, p=0.047 and
p<0.001, respectively).
Conclusions This study shows that the majority of drug-
related problems of community-dwelling older patients was
not associated with STOPP/START criteria. These findings
suggest that application of STOPP/STARTcriteria in full clin-
ical medication review should preferably be combined with
implicit criteria.
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Introduction
Polypharmacy and inappropriate medication use by older peo-
ple increase the risk of adverse drug reactions [1]. Inappropri-
ate medications are defined as medications for which the po-
tential risk outweighs the potential benefit [2]. Next to inap-
propriate medications, older patients with polypharmacy may
also be susceptible to under-prescribing. Under-prescribing of
medications refers to the omission of a drug when there is a
clear indication and no contra-indication [3].
Several tools are available to evaluate inappropriate medi-
cation and prescribing omissions in older patients, including
implicit and explicit criteria. Implicit criteria, like the Medica-
tion Appropriateness Index (MAI), consist of a structural as-
sessment of the patient’s medicines. They may rely on expert
professional judgment for their application. Although implicit
criteria have demonstrated their usefulness in detecting drug-
related problems in several studies, the application may be
rather time-consuming in practice [4–12].
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PHARMACOEPIDEMIOLOGYAND PRESCRIPTION
Explicit criteria consist of lists of inappropriate medications
and prescribing omissions in the elderly. The first explicit
criteria published for potentially inappropriate medications
were the Beers-criteria [2, 13–15]. These are the most widely
cited criteria for inappropriate medications, but the applicabil-
ity outside the USA is limited due to differences in types of
drugs and guidelines [16–18]. In 2008, two sets of European-
based criteria (STOPP and START) were formulated to ad-
dress the perceived deficiencies of Beers’ criteria and prescrib-
ing omissions as well [19]. Screening Tool of Older Persons
Prescriptions (STOPP) contains a list of 65 potentially inap-
propriate medications or medication classes. Screening Tool
to Alert doctors to Right Treatment (START) lists 22 potential
prescribing omissions (PPOs) in patients with particular med-
ical conditions [19].
Studies in older patients showed that STOPP criteria were
more sensitive than Beers criteria in identifying potentially
inappropriate medications [20–22]. However, there are no
studies that compared the use of these explicit criteria with
implicit criteria in the detection of drug-related problems.
Therefore, the aim of our study was to determine the number
and types of STOPP/START criteria present in identified
drug-related problems (DRPs) and recommendations found
by medication review with implicit criteria.
Methods
Study procedures and population
In 13 Dutch community pharmacies, a list of all community-
dwelling patients aged 65 years and older, using at least five
oral prescription drugs in 2011, was compiled using the phar-
macy information system. From this list, the pharmacists took
a convenience sample of patients to invite for a medication
review. Pharmacies were located in both urban regions in the
south-west of the Netherlands. Pharmacists received complete
medical data from the general practitioners (GPs), including
diagnoses and laboratory values, after agreement of the
patient.
Ethics
Medication reviews are provided as an enhanced service for
older people with polypharmacy by pharmacists and GPs in
the Netherlands. In order to protect the patient’s privacy, all
data were anonymised by the community pharmacists using a
randomly assigned unique number. The researchers only re-
ceived the anonymised written care plans of the medication
reviews. In addition, they received anonymised drug dispens-
ing records for each patient. Because this study was performed
retrospectively and used anonymised patient data, no ethical
approval was required according to current Dutch guidelines.
Medication review
The patient’s community pharmacist interviewed the patient
about his drugs at home or in the pharmacy. Patient’s concerns
and experiences regarding drug therapy (in particular percep-
tion of the effectiveness and potential adverse effects), adher-
ence issues, practical problems, understanding of their medi-
cation regimen and possible use of OTC (over the counter)
medication were addressed during this interview. A pharma-
ceutical care plan was proposed by the community pharmacist
using both the patient’s medication records from the pharma-
cy, general practitioners (GPs) medical records and the data
from the patient interview. Potential DRPs and associated rec-
ommendations were identified by implicit criteria based on a
structural assessment of indication, effectiveness, safety and
compliance byHepler and Strand [7]. Recommendations were
implemented after agreement between both the community
pharmacist, the general practitioner and the patient. Follow-
up of implemented recommendations was monitored by the
community pharmacists.
Participating community pharmacists had experience in
performing medication reviews. Therefore, they received an
accredited training course in medication review. The course
educated in clinical guidelines, communication skills, identi-
fying DRPs and designing pharmaceutical care plans. In ad-
dition, pharmacists participated in monthly web conference
sessions moderated by a medication review expert. During
these sessions, case studies and treatment guidelines were
discussed. Moreover, all pharmacists were observed and re-
ceived feedback on one medication review session.
Data classification
Drugs were classified using the Anatomical Therapeutic
Chemical (ATC) Classification System (11th edition, 2008)
formulated by the World Health Organization Collaborating
Centre for Drug Statistics Methodology. Potential DRPs and
recommendations were classified according to the
D.O.C.U.M.E.N.T. system by the community pharmacists
[12, 23–25].
Application of START-STOPP criteria
After completion of the medication reviews, the anonymised
results were sent to the investigators. The database with the
results consisted of registered DRP’s, ATC codes of the drugs
associated with the DRPs and interventions, recommenda-
tions and free text boxes with reasons to change a drug (e.g.
start ACE inhibitor because of heart failure). Based on these
results, STOPP and START criteria were retrospectively and
independently applied by two investigators (H.K. and S.V.).
Differences were discussed until consensus was reached. A
10 % sample of the DRPs was taken and also reviewed by
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two other investigators (A.F. and M.B.). For the application of
the STOPP/START criteria, the first version of the STOPP/
STARTcriteria was used [19]. Two adaptations of the original
criteria were made to make the criteria fit the current Dutch
guideline [8]. The STOPP criteria: “aspirin or NSAIDs with-
out a proton pump inhibitor” and “opiates without laxatives”,
were modified to START criteria [8].
Outcome measurements
The primary outcomes were number, type and implementation
rate of STOPP and START criteria applicable to identified
DRPs and associated recommendations during medication re-
view. The implementation rate was defined as the percentage
of recommendations that was fully or partly implemented ac-
cording to the community pharmacist.
Statistical analysis
All implementation rates of recommendations were analysed
on an intention-to-treat basis. Descriptive statistics were used
for basic characteristics. Pearson chi-square tests were used
for each categorical variable. A p value <0.05 was considered
statistically significant. All data were analysed using
Microsoft Access and Excel 2010 (Microsoft Corporation,




Twenty-one community pharmacists in 13 pharmacies collab-
orated with 65 GPs in this study. The pharmacists conducted
533 patient interviews. Clinical medication reviews were per-
formed for 461 of 533 patients. Seventy-two patients were
excluded because their medication reviews were not fully
completed. Of 461, another four patients were excluded dur-
ing follow-up because of death or hospital admission. Finally,
457 patients were included for analysis. The median age was
77 years (interquartile range 73–81), and 60 % were women
(Table 1). The most commonly prescribed drug classes were
“antithrombotic agents” (69 %) and “agents acting on the
renin-angiotensin system” (68 %).
STOPP and START criteria among identified DRPs
A total of 1656 potential DRPs were identified (mean 3.6 per
patient) (Table 2). Eighty-one percent of DRPs were not asso-
ciated with either STOPP or START criteria. The percentage
of START criteria present in identified DRPs was higher than
the percentage of STOPP criteria (13 vs. 5.7 %, p=0.001).
The majority of STOPP criteria was associated with DRP
type “drug selection” (59/94, 63 %), whereas START criteria
were associated with DRP type “undertreated” (205/214,
96 %). Both “undertreatment” and drug selection were more
frequently identified in the absence of either STOPP or
START criteria. Seventy-nine percent of the DRP type drug
selection and 57 % of the DRP type undertreated did not
comprise the criteria. The most common DRP type related
with the recommendation to cease a drug was “no indication
apparent” (186/338, 55 %). The most common DRP type
related with the recommendation to add a drug was an untreat-
ed symptom that emerged from the patient interview, e.g. pain,
itching or shortness of breath (32/275, 12 %).
Implementation rate of recommendations associated
with STOPP/START criteria
Thirty-five percent of DRPs were associated with a recom-
mendation to cease, replace or add a drug. The implementa-
tion rate for recommendations associated with STOPP criteria
was higher compared to recommendations associated with
START criteria (56 vs. 39 %, p=0.005). Both implementation
rates of recommendations associated with STOPP and START
criteria were lower compared to recommendations not associ-
ated with STOPP or START criteria (66 %, p=0.047 and
p<0.001, respectively, Table 3).
STOPP criteria were applicable to 79 of 338 recommenda-
tions to cease a drug (23 %). The implementation rate for
STOPP criteria was not different compared to other recommen-
dations to cease a drug (58 vs. 51 %, p=0.23). START criteria
Table 1 Baseline characteristics of participants (≥65 years and ≥5
drugs) n = 457
Socio demographic
Female (%) 60
Age (year, median, interquartile range) 77 (73–81)
Number of prescribed drugs (mean per patient, SD) 8.7 (3.2)
Most prescribed drug classes (ATC)
Antithrombotic agents (B01A) 69 %
Agents acting on the Renin-Angiotensin System (C09) 68 %
Lipid Modifying agents (C10A) 59 %
Beta blocking agents (C07A) 57 %
Drugs for peptic ulcer and GORD (A02B) 57 %
Drugs used in diabetes (A10) 33 %
High-ceiling diuretics (C03C) 31 %
Calcium channel blockers (C08C) 27 %
Low-ceiling diuretics (C03A, C03B, C03E) 24 %
Drugs for obstructive airway diseases (R03) 22 %
Benzodiazepine derivatives (N05BA, N05CD) 22 %
ATC Anatomical Therapeutic Chemical Classification System
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were applicable to 197 of 275 recommendations to add a drug
(72 %). The implementation rate for the subgroup START
criteria recommendations was lower compared to other recom-
mendations to add a drug (38 vs. 54 %, p=0.02) (Table 3).
Prevalence and types of STOPP/START criteria
STOPP criteria were present in 80 patients (17 %). Sixty-nine
patients had one potentially inappropriate drug, and 11 had
more than one. START criteria were present in 163 patients
(36 %). One hundred twenty-two patients had one potential
prescribing omission and 41 had more than one.
Nine types of STOPP criteria accounted for 82 % of
the total and 25 of the 65 available types of STOPP
criteria were present. The most prevalent STOPP criteria
were duplicate drug classes (N=19, 20 %), benzodiaze-
pines (N=12, 13%) and vasodilator drugs (N=12, 13 %)
(Table 4).
Table 2 Classification of identified DRPs by STOPP and START criteria
DRP type and subtype Not identified by STOPP/START Identified by STOPP Identified by START
N N (%)b N (%)b N (%)b
D(rug selection) 303 239 (79) 59 (19) 5 (2)
Duplication 20 3a (15) 17 (85) – –
Drug interaction 11 10 (91) 1 (9) – –
Contra-indication apparent 16 7 (44) 7 (44) 2 (12)
No indication apparent 256 219 (86) 34 (13) 3 (1)
O(ver or underdose) 200 199 (99) 1 (1) – –
Prescribed dosage too high 64 63 (99) 1 (1) – –
Prescribed dosage too low 52 52 (100) – – – –
Incorrect or unclear dosing instructions 84 84 (100) – – – –
C(ompliance) 142 139 (98) 1 (1) 2 (1)
Taking too little 72 69 (96) 1 (1) 2 (3)
Taking too much 8 8 (100) – – – –
Difficulty using dosage form 62 62 (100) – – – –
U(ndertreated) 507 289 (57) 13 (3) 205 (40)
Condition undertreated 380 215 (57) 12 (3) 153 (40)
Condition untreated 127 74 (58) 1 (1) 52 (41)
M(onitoring) 222 221 (99) – – 1 (1)
Laboratory monitoring 152 152 (100) – – – –
Non-laboratory monitoring 70 69 (99) – – 1 (1)
E(ducation or information) 62 62 (100) – – – –
Disease management or advice 62 62 (100) – – – –
N(on-clinical) 55 54 (98) 1 (2)
Other 55 54 (98) 1 (2)
T(oxicity) 165 145 (88) 19 (11) 1 (1)
Toxicity, allergic reaction or adverse effect present 165 145 (88) 19 (11) 1 (1)
Overall 1656 1348 (81) 94 (6) 214 (13)
Bold entries represent the most important outcomes
N number
a These three DRPs were mistakenly coded duplicate medication by the pharmacists. DRPs were (1) codeine and oxycodone (pseudo-duplicate), (2)
allopurinol and colchicine (overtreatment), and (3) two different dosages of doxazosine were in use simultaneously (dose too high)
b The percentage within DRP type or subtype
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Ten STARTcriteria accounted for 89 % of the total, and 18
of the 22 available START criteria were present. The most
common START criteria were calcium and vitamin D in oste-
oporosis (N=58, 27%), statins in coronary, cerebral or periph-
eral vascular disease (N=31, 14 %), and β-blockers in angina,
acute MI or heart failure (N=20, 9 %) (Table 5).
Discussion
This study shows that the majority (81 %) of DRPs
identified by pharmacists during a clinical medication
review was not associated with STOPP/START criteria.
START criteria identified twice as much DRPs com-
pared to STOPP criteria. In contrast, the implementation
rate of recommendations originating from STOPP
criteria was higher compared to recommendations origi-
nating from START criteria. Recommendations not
originating from STOPP/START criteria, however, had
a higher implementation rate than both STOPP and
START criteria.
The majority of DRPs (65 %) identified during medication
review is not associated with recommendations to cease, re-
place or add a drug, and could therefore not be detected with
STOPP/START criteria. Furthermore, only half of the recom-
mendations to cease or add a drug are associated with STOPP/
START criteria in this study. In particular, only 23 % of all
recommendations to cease a drug comprised a STOPP criteri-
on. The most important reason to cease a drug was no indica-
tion apparent for a drug. The majority of DRPs can therefore
only be detected by a structural assessment of the patient’s
medicines and diagnoses using the implicit criteria. These
findings underline the importance of using implicit criteria
for medication review and education of the community phar-
macist to develop the required medication review skills to use
them [26].
Table 3 Comparison of prevalence and implementation rate of recommendations to stop, add or replace a drug, associated with STOPP/START
criteria and implicit criteria
Type of recommendation No STOPP/START STOPP START P value
N IR N IR N IR
Cessation of drug 259 51% 79 58 % – – 0.23
Addition of a drug 78 54% – – 197 38 % 0.02
Replacement of drug 138 51%
15 47 % – – 0.75
– – 17 53 % 0.83
Other 873 75% – – – – –
1348 66%
Total 94 56 % – – 0.047
– – 214 39 % <0.001
Bold entries represent the most important outcomes
N number, IR implementation rate
Table 4 Implementation rates of
ten most frequent potentially
inappropriate medications
according to STOPP criteria
Inappropriate medication N IR (%)
Any duplicate drug class prescription 19 47
Drugs that adversely affect fallers: Benzodiazepines 12 67
Drugs that adversely affect fallers: Vasodilator drugs 12 50
Long-term (i.e. >1 month), long-acting benzodiazepines 7 71
Aspirin—not indicated 6 33
Oestrogens without progestagen in patients with intact uterus 5 100
NSAID with heart failure 5 80
Long-term NSAID or colchicine for chronic treatment of gout - no
contraindication to allopurinol
5 80
β-Blockers and frequent hypoglycaemic episodes 3 67
Long-term opiates in those with recurrent falls 2 50
N number, IR implementation rate
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START criteria were applicable to 36 % of patients which
was considerably higher than in the study of Ryan et al. (23%)
[27]. Eighteen of 22 criteria accounted for the prescribing
omissions in our study, while this was 15 in the study of Ryan
[27]. The high prevalence of START criteria in our study
together with the high proportion of recommendations to
add a drug associated with START criteria suggests a good
practical applicability of this tool for older patients with
polypharmacy in primary care. Other reasons to add a drug
were mainly based on the complaints of the patient that
emerged from the interview. These problems are diverse and
could not easily be converted into a START criterion.
The implementation rate of recommendations associated
with STOPP was comparable to other recommendations to
cease a drug. On the contrary, recommendations to add a
new drug based on STARTwere less frequently implemented
compared to other recommendations to add a drug. Especially,
recommendations to add cardiovascular drugs (e.g. statins,
ACE inhibitors and beta-blockers) were poorly implemented.
It is likely that GPs are cautious to change cardiovascular
treatment of patients who are concurrently seeing a specialist.
Furthermore, non-acceptance may be caused by the fact that
patients previously experienced adverse effects on these
drugs. Although these adverse effects are probably not always
that serious that rechallenge is unacceptable, patients will of-
ten be reluctant to restart such drugs. Finally, GPs may be
reluctant to add preventive drugs in the oldest old, because
risk factors such as high cholesterol levels and hypertension
for those patients may not be related to mortality [28, 29]. On
the contrary, addition of proton pump inhibitors and, to a
lesser extent, calcium and vitamin D had high implementation
rates. These drugs are characterised by a direct effect or by the
absence of serious adverse effects.
Our study had several strengths. First of all, the elaborate
description of DRPs and recommendations by the pharmacists
enabled retrospective identification of STOPP/START
criteria. Second, we used data from routinely performed
medication reviews involving a high number of community
pharmacists, GPs and patients. The results are therefore likely
to be representative for daily clinical practice in primary care.
There were some limitations to the study. First, we could
not directly apply the STOPP/START criteria because the re-
searchers, unlike the pharmacists, did not have access to med-
ical records (diagnoses and laboratory values). Therefore, the
study design did not allow for a direct comparison of a strat-
egy purely based on STOPP/START criteria and a strategy
based on implicit criteria. Although for a limited number of
STOPP criteria, clinical information is not required, and ac-
cess to the full clinical record is recommended for the majority
of STOPP and START criteria [30].
Despite this, STOPP criteria in our study were applicable to
18 % of the patients, which is slightly lower than the findings
of Ryan et al. in a comparable primary care population [27]. In
our study, 25 of 65 STOPP criteria were used, which is com-
parable to the study of Ryan et al. using 28 STOPP criteria [27,
30].
Second, the pharmacists who performed the medication
reviews did not have specific training in the application of
STOPP and START criteria. However, the pharmacists were
considered to have sufficient knowledge of the guidelines un-
derlying these explicit criteria, based on the training pro-
gramme and monthly web conferences. Still, it is likely that
applying the STOPP/STARTcriteria on the medication data of
the original population selected for medication review would
also have identified someDRPs that now have beenmissed by
the pharmacist. Thirdly, the implementation rate of recom-
mendations was based on self-report by the community phar-
macists and not on measurement of medication changes in
dispensing records. Finally, by including only patients taking
five or more medications, bias could be introduced by poten-
tial underestimation of prescribing omissions as detected by
START criteria.
Although STOPP/START criteria were present in a minor-
ity of all DRPs identified, especially, START criteria do seem
Table 5 Implementation rates of
ten most frequent potential
prescribing omissions according
to START criteria
Omitted medication—medical condition N IR (%)
Calcium and vitamin D supplement—osteoporosis 58 57
Statin therapy—history of coronary, cerebral or peripheral vascular disease 31 26
β-Blocker—angina, acute MI or heart failure 20 15
Proton pump inhibitor—ASA (≤100 mg) and >80 years, NSAID and >70 years or refluxa 19 79
Bisphosphonates—corticosteroids or osteoporosis 16 13
Statin therapy—diabetes mellitus 13 23
ACE inhibitor—heart failure 9 44
Metformin—type 2 diabetes or metabolic syndrome 9 22
ACE inhibitor or angiotensin receptor blocker—diabetes with nephropathy 8 50
Antihypertensive therapy—systolic blood pressure >160 mmHg 8 25
N number, IR implementation rate
a This STARTcriterion is an adapted version of the original STOPP criterion, as used in the Dutch guidelines [8]
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applicable as a screening tool for medication review in prima-
ry care. It has been suggested to incorporate STOPP and
START in existing information systems in primary care [27].
Such automated systems could facilitate medication review
but cannot replace a systematic approach using implicit
criteria. Finally, explicit criteria will remain susceptible to
changes, which are shown by the recently published second
version of the STOPP/START criteria [31]. Future research
should further establish the applicability of STOPP/START
criteria in medication review by incorporation of the tool into
the intervention.
Conclusion
This study shows a higher prevalence of START criteria com-
pared to STOPP criteria in identified DRPs of community-
dwelling older patients, while STOPP criteria are implement-
ed more frequently. Although STOPP/STARTcriteria identify
an important number of DRPs, the majority of DRPs identi-
fied during medication review was not associated with
STOPP/STARTcriteria.When used, STARTcriteria may have
a higher practical applicability compared to the extensive list
of STOPP criteria for medication review in primary care. The-
se findings suggest that health care providers cannot solely
depend on the STOPP/START criteria to identify DRPs in
primary care.
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